The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
|Videos|September 1, 2017
Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast Cancer
Author(s)Frankie Ann Holmes, MD
Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.
Advertisement
Advertisement
Related to this article
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Advertisement
Advertisement
Trending on OncLive
1
FDA Finalizes 3 Guidance Documents to Broaden Cancer Clinical Trial Eligibility Criteria
2
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
3
Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances
4
AI Tools Show Early Promise Across Drug Discovery, Clinical Decision-Making in Lung Cancer
5